Healthcare - Biotechnology - NASDAQ - US
$ 4.53
-3.41 %
$ 36.1 M
Market Cap
-1.52
P/E
CASH FLOW STATEMENT
-30.2 M
OPERATING CASH FLOW
-1.5 M
INVESTING CASH FLOW
42.2 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Clene Inc.
| Net Income | -49.5 M |
| Depreciation & Amortization | 1.7 M |
| Capital Expenditures | -330 K |
| Stock-Based Compensation | 9.12 M |
| Change in Working Capital | -191 K |
| Others | 9.97 M |
| Free Cash Flow | -30.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (49.5) | (29.9) | (9.7) | (19.3) | (16.2) | (0.3) |
| Depreciation & Amortization | 1.7 | 1.0 | 1.0 | 1.0 | 0.8 | 0.7 |
| Deferred Income Tax | 0 | 0 | (1.6) | 15.1 | 0.4 | 0 |
| Stock Based Compensation | 9.1 | 8.5 | 12.4 | 0.8 | 0.4 | 0.3 |
| Other Operating Activities | 8.7 | (17.1) | (37.6) | (13.2) | 0.2 | 46.6 K |
| Change in Working Capital | (0.2) | (1.5) | 1.0 | (3.3) | 1.2 | 0.1 |
| Cash From Operations | (30.2) | (39.0) | (34.6) | (18.9) | (13.2) | (0.2) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.3) | (5.2) | (1.3) | (0.4) | (0.3) | (0.8) |
| Other Items | (1.2) | (5.0) | 0 | 0 | 0 | (45.2) |
| Cash From Investing Activities | (1.5) | (10.2) | (1.3) | (0.4) | (0.3) | (46.0) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0.3 | 5.6 | 19.8 | 5.9 | (2.6) | 3.9 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.2) | 0.2 | 7.3 | 63.6 | 8.1 | 15.9 |
| Cash From Financing Activities | 42.2 | 17.2 | 27.1 | 69.5 | 5.5 | 46.9 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 10.5 | (32.0) | (8.9) | 50.5 | (8.0) | 0.8 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (30.5) | (44.2) | (36.0) | (19.3) | (13.5) | (1.0) |